Lethal catatonia, malignant neuroleptic syndrome and myositis ossificans Katatonie, malignes neuroleptisches Syndrom und Myositis ossificans;Katatonie, malignes neuroleptisches syndrom und myositis ossificans

Nervenarzt

Volumn 67, Issue 5, 1996, Pages 413-417

  Topka, H ^a   Buchkremer, G ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Lethal catatonia; Malignant neuroleptic syndrome; Myositis ossificans

Indexed keywords

BENPERIDOL; CLOZAPINE; DIAZEPAM; HALOPERIDOL; NEUROLEPTIC AGENT; TRIFLUPERIDOL;

ADULT; ARTICLE; CASE REPORT; CATATONIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROLEPTIC MALIGNANT SYNDROME; ORAL DRUG ADMINISTRATION; OSSIFYING MYOSITIS; STUPOR;

ADULT; ANTIPSYCHOTIC AGENTS; CATATONIA; DRUG THERAPY, COMBINATION; HUMANS; MALE; MYOSITIS OSSIFICANS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; SCHIZOPHRENIA, CATATONIC;

EID: 0029945420     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ackerman LV (1958) Extra-osseus localized non-neoplastic bone and cartilage formation (so called myositis ossificans). J Bone Joint Surg [Am] 40: 279-298
2. Adityanjee SS (1991) The myth of elevated serum creatin phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 158: 706-707
3. Brenner I, Rheuban WJ (1978) The catatonic dilemma. Am J Psychiatry 135: 1242-1243
4. Caroff SN, Mann SC, Lazarus A, Sullivan K, MacFadden W (1991) Neuroleplic malignant syndrome: diagnostic issues. Psychiatr Ann 21: 130-147
5. Castillo E, Rubin RT, Holsboer TE (1989) Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 146: 324-328
6. Craddock B, Craddock N, Milner G (1991) Creatinphosphokinase in neuroleptic malignant syndrome. Br J Psychiatry 158: 130
7. Delay J, Deniker P (1968) Drug-induced extrapyramidal syndromes. In: Viken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 6. North Holland, Amsterdam, pp 248-266
8. Gaertner HJ, Hörner W, Bartels M (1983) Katatoniforme Symptome als Nebenwirkung neuroleptischer Behandlung. Nervenarzt 54: 250-254
9. Häfner H, Kasper S (1982) Akute lebensbedrohliche Katatonie: Epidemiologische und klinische Befunde. Nervenarzt 53: 385-394
10. Harsch HH (1987) Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. J Clin Psychiatry 48: 328-333
11. Mann SC, Caroff SN, Bleier HR et al (1986) Lethal catatonia. Am J Psychiatry 143: 1374-1381
12. Raja M, Altavista MC, Cavallari S, Lubich L (1994) Neuroleptic malignant syndrome and catatonia. Eur Arch Psychiatry Clin Neurosci 243: 299-303
13. Rompe G (1986) Muskelverknöcherungen. In: Jäger M, Wirth CJ (Hrsg) Praxis der Orthopädie. Thieme, Stuttgart, S 565-567
14. Rosebush P, Mazurek M (1991) Serum iron and the neuroleptic malignant syndrome. Lancet 338: 149-151
15. Rosebush PI, Hildebrand AM, Mazurek MF (1992) The treatment of catatonia: Benzodiazepines or ECT? Am J Psychiatry 149: 1279-1280
16. Schmidt RM, Zacher G (1974) Bedrohliche Katatonie: Entität oder multigenetisches Syndrom? Übersicht und Untersuchung an 50 Fällen. Psychiatr Clin (Basel) 7: 65-74
17. Weller M, Kornhuber J (1992) Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. Nervenarzt 63: 645-655
18. White DA (1992) Catatonia and the neuroleptic malignant syndrome: a single entity? Br J Psychiatry 161: 558-560
19. White DA, Robins AH (1991) Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 158: 419-421